Facilitating rapid discovery and development of potentially predictive signatures with the most advanced view of immuno-oncology biology.
The PanCancer IO 360 Gene Expression Panel is a unique 770 gene expression panel for research use only (RUO) that combines vital components involved in the complex interplay between the tumor, microenvironment and immune response in cancer allowing for a multifaceted characterization of disease biology and interrogation of mechanisms of immune evasion.
Developed specifically for translational research, this powerful new panel incorporates 47 potentially predictive Research Use Only (RUO) biological signatures including the 18-gene Tumor Inflammation Signature as recently described in JCI.1
- Translational RUO panel for the research of possible predictive signatures for potential immunotherapy companion diagnostics
- Allows for possible identification of responder/non-responder populations for immunotherapy research
- Characterize disease biology
- Interrogate mechanisms of immune evasion
Download Gene Lists:
Possible predictive signatures measuring IO biology trained through combination of domain knowledge, academic collaborations and mining of public and proprietary data.
13 Biological Pathways and Processes
|Category/Gene Number||Category/Gene Number||Category/Gene Number|
|Release of Cancer Cell Antigens||74||Angiogenesis||40||Cancer Antigen Presentation||95|
|Cell Cycling and Proliferation||54||Extracellular Matrix Remodelling||43||T cell priming and Activation||151|
|Tumor Intrinsic Factors||156||Collagens||6||Immune Cells Localization to Tumors||293|
|Common Signaling Pathways||172||Metastasis||20||Recognition of Cancer Cells by T cells||103|
|Killing of Cancers Cells||177|
|Myeloid Cell Activity||262|
|NK Cell Activity||28|
20 internal reference genes include overlapping genes from Hallmarks of Cancer PanCancer Collection for cross-panel comparisons.
Tumor Inflammation Signature1
The Tumor Inflammation Signature includes 18 functional genes known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade.
Includes 4 Areas of Immune Biology: IFN-ү-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes.
The tumor inflammation gene expression signature highlights the complex biology of the host immune microenvironment.
|18-gene Tumor Inflammation Signature|
1. Ayers, Mark, et al. "IFN-y-related mRNA profile predicts clinical response to PD-1 blockade." The Journal of Clinical Investigation 127.8 (2017).
|Number of Targets||770 (Human and Mouse), Including internal reference genes|
|Sample Input – Standard (No amplification required)||50 – 300 ng|
|Sample Input – Low Input||As little as 10 ng with nCounter RNA Low Input Kit and Panel specific primer pools (sold separately)|
|IO 360 Panel Standard||Synthetic oligonucleotide pool corresponding to all panel gene targets used for normalization|
|Sample Type(s)||FFPE-derived RNA, total RNA, and cell lysates|
|Customizable||Add up to 30 unique genes with Panel-Plus|
|Time to Results||Approximately 24 hours|
|Data Analysis||nSolver Analysis software, IO 360 Data Analysis Service|
Ayers, Mark, et al. "IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade." The Journal of Clinical Investigation 127.8 (2017).
Danaher, Patrick, et al. "Gene expression markers of Tumor Infiltrating Leukocytes." Journal for immunotherapy of cancer 5.1 (2017): 18.
Satoh, Jun-ichi, and Hiroko Tabunoki. "A comprehensive profile of ChIP-Seq-based STAT1 target genes suggests the complexity of STAT1-mediated gene regulatory mechanisms." Gene regulation and systems biology 7 (2013): 41.
Becht, Etienne, et al. "Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression." Genome biology 17.1 (2016): 218.
Spranger, Stefani, Riyue Bao, and Thomas F. Gajewski. "Melanoma-intrinsic [beta]-catenin signalling prevents anti-tumour immunity." Nature 523.7559 (2015): 231.
Harris, B. H. L., et al. "Gene expression signatures as biomarkers of tumour hypoxia." Clinical Oncology 27.10 (2015): 547-560.
Manson, G., et al. "Biomarkers associated with checkpoint inhibitors." Annals of Oncology 27.7 (2016): 1199-1206.
Blank, Christian U., et al. "The “cancer immunogram”." Science 352.6286 (2016): 658-660.
For Research Use Only. Not for use in diagnostic procedures.